Skip to main content

Table 3 Baseline Physician and Practice Characteristics

From: Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial

 

Overall

Intervention

Control

Int vs, Control

p-value

 

n = 129

n = 67

n = 62

 

Age (Average / SD)

50.1 (8.9)

49.0 (8.9)

51.2 (8.9)

0.133

Number of years post-fellowship

 0–5

7.2%

10.2%

3.8%

0.410

 6–10

17.3%

18.1%

16.3%

 11–20

45.1%

47.5%

42.3%

 21+ years

30.5%

24.1%

37.7%

Number of MD’s associated with practice

 1–3

33.9%

34.8%

32.8%

0.816

 4–10

35.5%

33.9%

37.4%

 10+

30.6%

31.3%

29.8%

 Single Specialty Practice (%)

86.3%

85.7%

87.0%

Practice type (% breakdown)

 Group/Staff

85.9%

82.1%

90.2%

0.410

 IPA

4.6%

4.8%

4.3%

 Mixed

7.9%

10.2%

5.4%

 Network

1.5%

2.9%

0.0%

Practice Ownership (% breakdown)

 Physician-Physician group

89.3%

93.1%

85.1%

0.246

 Hospital

6.3%

4.1%

8.9%

 Community Health Center

3.4%

1.4%

5.7%

 Other

0.9%

1.4%

0.3%

Employed by practice (% Yes)

65.3%

66.7%

63.8%

0.713

Average days worked per week (%)

 4

11.0%

14.3%

7.2%

0.568

 5+

89.0%

85.7%

92.8%

On-site robotic surgery capability (%)

55.5%

51.9%

59.4%

0.364

Number of urology patients seen in 1 week

  < 50

1.6%

1.4%

1.9%

0.861

 51–100

49.6%

48.9%

50.4%

  > 100

48.7%

49.6%

47.7%

Number of prostate cancer patients seen in 1 week

 0–20

58.3%

47.3%

70.8%

0.005

  > 20

41.7%

52.7%

29.2%

Proportion of all patients covered by (sd)

 Medicare

47.6 (11.6)

48.4 (11.8)

46.7 (11.5)

0.379

 Commercial

41.3(13.3)

40.3 (13.0)

42.5 (13.6)

0.316

 Medicaid

6.1(6.4)

6.1 (5.9)

6.2 (6.9)

0.966

 Self-pay

3.7 (4.0)

3.7 (3.8)

3.7 (4.3)

0.989